Fouad Namouni
About Fouad Namouni
Fouad Namouni President of Research & Development
Fouad Namouni currently holds the position of President of Research & Development. In this role, he is tasked with overseeing and driving the company's research initiatives and development strategies. His extensive experience in oncology and cancer immunotherapy significantly contributes to the company's efforts in these critical areas.
Fouad Namouni Education and Training
Fouad Namouni earned his M.D. from the University of Annaba Medical School in Algeria, laying the foundation for his medical career. He further specialized by obtaining a Pediatrics degree from Université Rene Descartes in Paris, France. Moreover, he holds a Pediatric Oncology and Hematology degree and a Master of Science in clinical and experimental pharmacology from Université Paris-Sud in France. These qualifications have equipped him with a robust academic background in medical and pharmaceutical sciences.
Fouad Namouni Oncology and Cancer Immunotherapy Expertise
Fouad Namouni brings over 20 years of expertise in oncology and cancer immunotherapy drug development. His in-depth knowledge and experience in these areas underpin his significant contributions to medical research and pharmaceutical advancements. He has been pivotal in advancing treatments and therapeutic strategies in the field of oncology.
Fouad Namouni Leadership Roles at Bristol-Myers Squibb
At Bristol-Myers Squibb, Fouad Namouni held various leadership roles, including serving as the global development lead for the company's cancer immunotherapy franchise. From August 2016 to April 2020, he served as Senior Vice President and Head of Oncology Development. Additionally, from September 2015 to September 2017, he was Head of Global Medical Affairs, managing 1,700 employees worldwide. Earlier, he led the development of Opdivo (nivolumab) and Yervoy (ipilimumab) from January 2011 to September 2015.